Glenpram 20 mg (Escitalopram Oxalate)

Adult administration

Safety has not been established for doses exceeding 20 mg per day. This medication is administered once daily in the morning or evening, with or without food. (1) Major depressive disorder: The usual dosage is 10 mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20 mg per day. If the dose is to be increased to 20 mg, it should be increased at intervals of at least 1 week. In general, 2-4 weeks are needed for antidepressant effects to become apparent. Even after symptoms have resolved, at least 6 months of drug treatment is required to ensure a therapeutic effect. (2) Panic disorder with or without agoraphobia: The recommended starting dosage is 5 mg per day for 1 week, followed by an increase to 10 mg per day. Depending on the patient's response, the dose may be increased to a maximum of 20 mg per day. The maximum effect occurs after approximately 3 months. The safety and efficacy of long-term administration of this medication for more than 10 weeks in the treatment of panic disorder have not been systematically studied. The physician should periodically reassess each patient to determine the need for continued treatment. (3) Social anxiety disorder: The usual dosage is 10 mg once daily. In general, 2-4 weeks are needed for symptoms to improve. Thereafter, depending on the patient's response, the dose may be reduced to 5 mg per day or increased to a maximum of 20 mg per day. Social anxiety disorder is a chronic condition, and continued treatment for 12 weeks is recommended to ensure a therapeutic effect. Long-term treatment of patients who responded was studied for 6 months and should be considered for each patient to prevent relapse. The usefulness of long-term treatment should be reassessed regularly. (4) Generalized anxiety disorder: The recommended starting dosage is 10 mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20 mg per day after at least 1 week of treatment. A long-term treatment trial was conducted in patients who responded to 12 weeks of open-label treatment, with 20 mg per day administered for at least 6 months. The physician should regularly reassess the usefulness of long-term treatment with this medication for each patient. (5) Obsessive-compulsive disorder: The usual dosage is 10 mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20 mg per day. A long-term treatment trial was conducted in patients who responded to 16 weeks of open-label treatment, with 10 mg or 20 mg per day administered for at least 24 weeks. Because obsessive-compulsive disorder is a chronic condition, treatment should be continued for a sufficient period to ensure symptom recovery. When this medication is used long-term, the benefit for each patient and the dosage should be reassessed regularly. 2) Patients with renal impairment No dose adjustment is needed in patients with mild or moderate renal impairment. Caution should be exercised in patients with severe renal impairment (CLCR < 30 mL/min). 3) Patients with hepatic impairment A starting dose of 5 mg per day for the first 2 weeks is recommended. Depending on the patient's response, the dose may be increased to 10 mg per day. 4) Discontinuation When discontinuing this medication, the dose should be gradually reduced over at least 1-2 weeks to avoid the possibility of withdrawal symptoms. 5) Switching from MAO inhibitors used to treat psychiatric disorders When discontinuing an MAO inhibitor used to treat psychiatric disorders and starting treatment with this medication, an interval of at least 14 days must be observed. Conversely, at least 14 days must elapse after discontinuing this medication before starting an MAO inhibitor to treat psychiatric disorders. 6) Other MAO inhibitors, such as linezolid or methylene blue Patients receiving linezolid or intravenous methylene blue should not start this medication because of the increased risk of serotonin syndrome. For patients who require other interventions, including hospitalization, or more urgent treatment of a psychiatric condition, treatment should be considered. It may be necessary to urgently administer linezolid or intravenous methylene blue to a patient already receiving this medication. If no alternative to linezolid or intravenous methylene blue is available and the benefits of treatment with linezolid or intravenous methylene blue are judged to outweigh the risk of serotonin syndrome in a particular patient, this medication may be discontinued immediately and linezolid or intravenous methylene blue administered. The patient should be monitored for symptoms of serotonin syndrome for 2 weeks after administration of linezolid or intravenous methylene blue, or until 24 hours after the last dose, whichever occurs first. Treatment with this medication may be restarted 24 hours after the last dose of linezolid or intravenous methylene blue. The risk associated with administration of methylene blue by non-intravenous routes (oral tablets or local injection), or with intravenous injection of this medication at a dose of 1 mg/kg or less, is unclear. Nevertheless, clinicians should be aware of the possibility of emergency symptoms of serotonin syndrome with these uses.

This medication is an antidepressant used to treat symptoms related to depression. During treatment, there may be an increase in suicidal thoughts or behaviors, especially in young patients aged 18 to 24, thus careful monitoring by a physician is necessary. This medication may cause serious side effects when taken with certain drugs, so patients must inform their doctor if they are taking other medications. Patients with angle-closure glaucoma or a history of glaucoma should be cautious about increased intraocular pressure when using this medication. Initial side effects such as nausea, anxiety, and insomnia may occur in the first 1 to 2 weeks after starting treatment, but they tend to lessen over time. During treatment, behavioral changes such as anxiety, restlessness, and aggression may occur, so family members or caregivers should closely observe the patient's condition. Sodium levels may drop in blood tests, and regular monitoring is particularly needed for the elderly or patients with liver disease. This medication can affect heart rhythm, so caution is required for patients with pre-existing heart conditions or prolonged QT intervals. If treatment is suddenly stopped, withdrawal symptoms such as dizziness, anxiety, and sleep disturbances may occur, so the dosage should be gradually reduced according to the doctor's instructions. Pregnant or nursing women should consult a doctor before taking this medication, and caution is needed as it may be passed into breast milk. The elderly should start with a lower dose for safety, and caution may be necessary when driving or operating machinery. In case of overdose, central nervous system disturbances, gastrointestinal issues, or cardiac arrhythmias may occur, requiring immediate medical attention. This medication is not recommended for children and adolescents as its safety and efficacy have not been sufficiently proven for this population. When storing the medication, it should be kept out of reach of children, and transferring it to another container may reduce its quality.

Thrombocytopenia, anaphylactic reaction, inappropriate secretion of antidiuretic hormone, hyperprolactinemia, decreased appetite, increased appetite, weight gain, weight loss, hyponatremia, loss of appetite, anxiety, restlessness, abnormal dreams, decreased libido, hypoactive sexual desire disorder, bruxism, agitation, hyperesthesia, panic attacks, confusion, aggression, depersonalization, hallucinations, mania, suicidal ideation, suicidal behavior, insomnia, drowsiness, dizziness, perceptual disturbances, tremors, taste disorders, sleep disorders, syncope, serotonin syndrome, dyskinesia, movement disorders, convulsions, psychomotor agitation, akathisia, mydriasis, visual impairment, tinnitus, tachycardia, bradycardia, QT prolongation on ECG, polymorphic ventricular tachycardia, ventricular arrhythmia, orthostatic hypotension, sinusitis, yawning, nosebleed, nausea, diarrhea, constipation, vomiting, thirst, gastrointestinal bleeding, hepatitis, abnormal liver function tests, increased sweating, urticaria, hair loss, rash, itching, petechiae, angioedema, arthralgia, myalgia, rhabdomyolysis, urinary retention, ejaculation disorder, erectile dysfunction, uterine bleeding, menorrhagia, galactorrhea, postpartum hemorrhage, fatigue, fever, edema, headache, dry mouth, abdominal pain, indigestion, enteritis, sensory abnormalities, cough, asthma, shortness of breath, fracture, palpitations, hypertension, paralysis, extrapyramidal disorders, migraine, hallucinations, asthma, shortness of breath, fracture, arthralgia, hypertension, dry mouth, tremor, weight gain, abdominal discomfort, anxiety, insomnia, visual hallucinations, frequent urination, sedation, heartburn, nausea, vomiting, diarrhea, palpitations, emotional instability, irritability, visual impairment

This medication is sensitive to light, so it should be stored in a container that blocks light. It is also recommended to keep the medication at room temperature between 1 to 30 degrees Celsius. This storage method helps maintain the medication's effectiveness and prevents deterioration.

Appearance

White oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle